Indocyanine green (icg) modification for treatment of liver cancer
AssigneeChildren's Medical Center Corporation
InventorKhashayar Vakili
Life of this patent
Estimating the term…
Loading patent…
AssigneeChildren's Medical Center Corporation
InventorKhashayar Vakili
Estimating the term…
The present disclosure provides compounds of Formula (I) and (I′), which are derivatives of indocyanine green (ICG), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, or prodrugs thereof, and methods of diagnosing, treating, or preventing diseases by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, or prodrugs thereof, or pharmaceutical compositions thereof. The present disclosure also provides methods of preparation of compounds of Formula (I) and (I′).
A compound of Formula I:
A compound of Formula I′:
The compound of any one of the preceding claims, wherein the compound is of Formula I-a-i, Formula I-a-ii, or Formula I-a-iii:
The compound of any one of the preceding claims, wherein the compound is of Formula I-b:
The compound of any one of the preceding claims, wherein the compound is of Formula I-b-i:
The compound of any one of the preceding claims, wherein the compound is of Formula I-c:
The compound of any one of the preceding claims, wherein the compound is of Formula I-c-i:
The compound of any one of the preceding claims, wherein the compound is of Formula I-d:
The compound of any one of the preceding claims, wherein the compound is of Formula I-d-i:
The compound of any one of the preceding claims, wherein each occurrence of RA is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
The compound of any one of the preceding claims, wherein at least one occurrence of RA is optionally substituted alkyl.
The compound of any one of the preceding claims, wherein at least one occurrence of RA is alkyl substituted with one or more optionally substituted amino groups.
The compound of any one of the preceding claims, wherein at least one occurrence of RA is alkyl substituted with one or more acyl groups.
The compound of any one of the preceding claims, wherein at least one occurrence of RA is alkyl substituted with halogen.
The compound of any one of the preceding claims, wherein at least one occurrence of RA is alkyl substituted with fluorine.
The compound of any one of the preceding claims, wherein at least one occurrence of RA is alkyl substituted with 18F.
The compound of any one of the preceding claims, wherein the compound is of Formula I-e:
The compound of any one of the preceding claims, wherein the compound is of Formula I-e-i:
The compound of any one of the preceding claims, wherein the compound is of Formula I-f:
The compound of any one of the preceding claims, wherein the compound is of Formula I-f-i:
The compound of any one of the preceding claims, wherein the compound is of Formula I-g:
The compound of any one of the preceding claims, wherein the compound is of Formula I-g-i:
The compound of any one of the preceding claims, wherein Rb1 is optionally substituted aryl or optionally substituted heteroaryl.
The compound of any one of the preceding claims, wherein Rb1 is aryl substituted with halogen.
The compound of any one of the preceding claims, wherein Rb1 is aryl substituted with fluorine.
The compound of any one of the preceding claims, wherein Rb1 is aryl substituted with 18F.
The compound of any one of the preceding claims, wherein Rb1 is heteroaryl substituted with halogen.
The compound of any one of the preceding claims, wherein Rb1 is heteroaryl substituted with fluorine.
The compound of any one of the preceding claims, wherein Rb1 is heteroaryl substituted with 18F.
The compound of any one of the preceding claims, wherein the compound is of Formula I-h:
The compound of any one of the preceding claims, wherein the compound is of Formula I-h-i:
The compound of any one of the preceding claims, wherein R3 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
The compound of any one of the preceding claims, wherein R3 is optionally substituted heterocyclyl.
The compound of any one of the preceding claims, wherein R3 is an optionally substituted azacyclooctyne.
The compound of any one of the preceding claims, wherein R3 is an optionally substituted aza-dibenzocyclooctyne.
The compound of any one of the preceding claims, wherein the compound is of Formula I-h-ii or I-h-iii:
The compound of any one of the preceding claims, wherein Rc1 is optionally substituted alkyl.
The compound of any one of the preceding claims, wherein Rc1 is alkyl substituted with halogen.
The compound of any one of the preceding claims, wherein Rc1 is alkyl substituted with fluorine.
The compound of any one of the preceding claims, wherein Rc1 is alkyl substituted with 18F.
The compound of any one of the preceding claims, wherein the compound is of Formula
The compound of any one of the preceding claims, wherein m is 5.
The compound of any one of the preceding claims, wherein n is 2.
The compound of any one of the preceding claims, wherein p is 2.
The compound of any one of the preceding claims, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein the at least one radioisotope is 11C, 18F, 13N, 15O, 64Cu, 67Cu, 67Ga, 68Ga, 75Se, 81mKr, 82Rb, 99mTc, 111In, 123I, 125I, 131I, or 133Xe.
The compound of any one of the preceding claims, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein the at least one radioisotope is 11C, 18F, 13N, 15O, 75Se, 123I, 125I, or 131I.
The compound of any one of the preceding claims, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein the radioisotope is 18F.
The compound of any one of the preceding claims, wherein the compound is of formula:
The compound of any one of the preceding claims, wherein the compound degrades less than 10% one hour after preparing the compound.
The compound of any one of the preceding claims, wherein the compound degrades less than 10% two hours after preparing the compound.
A pharmaceutical composition comprising:
A method of preparing a compound of Formula I-g-i:
Dependencies are inferred from the claim text.